跳至主要内容
临床试验/CTRI/2020/06/026064
CTRI/2020/06/026064招募中未知

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development-A Randomized Placebo Controlled Trial-a pilot study.

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Patients who are above 18 years of age
  • 2) Patients with Cirrhosis and SBP (community acquired /Health care associated/ nosocomial) with baseline Creatinine <1mg/dl, Bilirubin <4mg/dl

排除标准

  • 1) Antibiotic treatment within one week before the diagnosis of SBP (except for prophylactic treatment with norfloxacin)
  • 2) Significant cardiac failure, pulmonary disease
  • 3) Known Chronic Kidney Disease or findings suggestive of organic nephropathy (proteinuria, haematuria, or abnormal findings on renal USG)
  • 4) Hepatocellular carcinoma
  • 5) HIV infection;
  • 6) GI bleed within 1 month before the study
  • 7) Grade 3 to 4 hepatic encephalopathy
  • 8) Other types of infection
  • 10) Serum Bilirubin >=4 mg/dL and Serum Creatinine >= 1 mg/dl at presentation
  • 11) Patients requiring Albumin for any other indication.
  • 12) Presence of any potential causes of dehydration (such as diarrhea or an intense response to diuretic treatment) within one week before the diagnosis of SBP).

研究者

相似试验